



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SEP - 2 1998


Herbert Goodman, Esq.
FRITZHAUF, HOLTZ, GOODMAN,
LANGER & CHICK, P.C.
767 Third Ave. 25th Floor
New York, NY 10017-2023

Re: Patent Term Extension
Application for
U.S. Patent No. 4,572,912

Dear Mr. Goodman:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,572,912 for a period of 1,534 days.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.



Karin Tyson
Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: PRELAY™ and REZULIN™ (troglitazone)
FDA Docket No.: 97E-0145

kt

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

PATENT NO. : 4,572,912
ISSUED : February 25, 1986
INVENTOR(S) : Takao Yoshioka et al.
PATENT OWNER : Sankyo Company Limited

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

1,534 days

from August 28, 2004, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 2nd day of September 1998.



Bruce A. Lehman

Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks